| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 31 | 2017 | 1109 | 3.060 |
Why?
|
| Cyclohexanecarboxylic Acids | 11 | 2013 | 60 | 1.890 |
Why?
|
| Amines | 11 | 2013 | 98 | 1.840 |
Why?
|
| Substance Withdrawal Syndrome | 20 | 2013 | 435 | 1.790 |
Why?
|
| gamma-Aminobutyric Acid | 12 | 2013 | 208 | 1.770 |
Why?
|
| Anticonvulsants | 15 | 2007 | 223 | 1.610 |
Why?
|
| Cues | 16 | 2017 | 654 | 1.560 |
Why?
|
| Naltrexone | 10 | 2017 | 195 | 1.430 |
Why?
|
| Alcohol Drinking | 14 | 2014 | 805 | 1.100 |
Why?
|
| Valproic Acid | 7 | 2012 | 93 | 0.810 |
Why?
|
| Alcohol-Related Disorders | 3 | 2015 | 95 | 0.760 |
Why?
|
| Narcotic Antagonists | 10 | 2017 | 184 | 0.750 |
Why?
|
| Brain | 11 | 2017 | 2176 | 0.750 |
Why?
|
| Cocaine-Related Disorders | 9 | 2014 | 504 | 0.730 |
Why?
|
| Brain Mapping | 9 | 2017 | 532 | 0.670 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2017 | 2223 | 0.630 |
Why?
|
| Ethanol | 11 | 2012 | 893 | 0.620 |
Why?
|
| Flumazenil | 3 | 2013 | 23 | 0.610 |
Why?
|
| Reward | 4 | 2017 | 201 | 0.580 |
Why?
|
| Acetates | 4 | 2001 | 74 | 0.560 |
Why?
|
| Receptors, Opioid, mu | 3 | 2017 | 70 | 0.540 |
Why?
|
| Substance-Related Disorders | 8 | 2017 | 1242 | 0.530 |
Why?
|
| Adult | 46 | 2017 | 21403 | 0.500 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2012 | 82 | 0.500 |
Why?
|
| Lorazepam | 5 | 2009 | 54 | 0.490 |
Why?
|
| Motivation | 6 | 2014 | 561 | 0.480 |
Why?
|
| Quinoxalines | 1 | 2014 | 78 | 0.450 |
Why?
|
| GABA Agents | 3 | 2005 | 18 | 0.450 |
Why?
|
| Benzazepines | 1 | 2014 | 104 | 0.450 |
Why?
|
| Male | 54 | 2017 | 37321 | 0.440 |
Why?
|
| Nicotinic Agonists | 1 | 2014 | 111 | 0.440 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2013 | 128 | 0.420 |
Why?
|
| Quinolones | 2 | 2010 | 60 | 0.420 |
Why?
|
| Humans | 68 | 2017 | 68618 | 0.410 |
Why?
|
| Basal Ganglia | 2 | 2012 | 45 | 0.410 |
Why?
|
| Corpus Striatum | 2 | 2011 | 279 | 0.410 |
Why?
|
| Craving | 1 | 2014 | 200 | 0.400 |
Why?
|
| Functional Neuroimaging | 1 | 2012 | 82 | 0.400 |
Why?
|
| Piperazines | 2 | 2010 | 206 | 0.400 |
Why?
|
| Genetic Variation | 1 | 2012 | 220 | 0.390 |
Why?
|
| Antipsychotic Agents | 3 | 2010 | 247 | 0.390 |
Why?
|
| Female | 46 | 2017 | 38074 | 0.370 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2014 | 237 | 0.350 |
Why?
|
| Middle Aged | 34 | 2017 | 21147 | 0.350 |
Why?
|
| Narcotics | 2 | 2008 | 65 | 0.340 |
Why?
|
| Alcohol Deterrents | 3 | 2005 | 86 | 0.340 |
Why?
|
| Double-Blind Method | 13 | 2013 | 1738 | 0.330 |
Why?
|
| Central Nervous System Stimulants | 2 | 2017 | 221 | 0.320 |
Why?
|
| Hypnotics and Sedatives | 1 | 2009 | 96 | 0.320 |
Why?
|
| Ondansetron | 1 | 2008 | 13 | 0.310 |
Why?
|
| Serotonin Antagonists | 1 | 2008 | 31 | 0.310 |
Why?
|
| Treatment Outcome | 18 | 2017 | 7029 | 0.300 |
Why?
|
| Behavior, Addictive | 5 | 2013 | 317 | 0.300 |
Why?
|
| Cocaine | 5 | 2013 | 555 | 0.290 |
Why?
|
| Secondary Prevention | 8 | 2013 | 291 | 0.290 |
Why?
|
| Alcohol Withdrawal Delirium | 3 | 2006 | 24 | 0.290 |
Why?
|
| Taurine | 2 | 2004 | 51 | 0.290 |
Why?
|
| Alcohol-Induced Disorders | 1 | 2005 | 5 | 0.270 |
Why?
|
| Severity of Illness Index | 8 | 2017 | 1851 | 0.270 |
Why?
|
| Nipecotic Acids | 1 | 2005 | 11 | 0.270 |
Why?
|
| GABA Agonists | 1 | 2005 | 23 | 0.260 |
Why?
|
| Benzodiazepines | 2 | 2006 | 130 | 0.260 |
Why?
|
| Implosive Therapy | 3 | 2012 | 171 | 0.260 |
Why?
|
| Culture | 1 | 2005 | 75 | 0.250 |
Why?
|
| Fructose | 1 | 2004 | 51 | 0.240 |
Why?
|
| Psychotherapy, Group | 1 | 2005 | 55 | 0.240 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2004 | 17 | 0.240 |
Why?
|
| Photic Stimulation | 5 | 2013 | 229 | 0.230 |
Why?
|
| Pilot Projects | 6 | 2014 | 1342 | 0.230 |
Why?
|
| Benzhydryl Compounds | 1 | 2004 | 62 | 0.230 |
Why?
|
| Narcolepsy | 1 | 2004 | 45 | 0.230 |
Why?
|
| Mood Disorders | 1 | 2004 | 132 | 0.220 |
Why?
|
| Carbamazepine | 5 | 2005 | 108 | 0.220 |
Why?
|
| Antimanic Agents | 1 | 2003 | 21 | 0.220 |
Why?
|
| Social Behavior | 1 | 2004 | 164 | 0.210 |
Why?
|
| Veterans | 5 | 2014 | 904 | 0.210 |
Why?
|
| Smoking Cessation | 3 | 2012 | 1034 | 0.210 |
Why?
|
| Stress Disorders, Post-Traumatic | 5 | 2014 | 1506 | 0.210 |
Why?
|
| Tobacco Use Disorder | 2 | 2011 | 432 | 0.200 |
Why?
|
| Combat Disorders | 2 | 2014 | 102 | 0.200 |
Why?
|
| Telemedicine | 2 | 2012 | 700 | 0.200 |
Why?
|
| GABA Modulators | 2 | 2013 | 26 | 0.190 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2017 | 257 | 0.190 |
Why?
|
| Young Adult | 7 | 2014 | 5717 | 0.190 |
Why?
|
| Analysis of Variance | 7 | 2013 | 1040 | 0.180 |
Why?
|
| Drug Therapy | 1 | 2001 | 71 | 0.180 |
Why?
|
| Demography | 3 | 2005 | 279 | 0.180 |
Why?
|
| Recurrence | 5 | 2013 | 948 | 0.170 |
Why?
|
| Drug Therapy, Combination | 5 | 2013 | 649 | 0.160 |
Why?
|
| Psychiatric Status Rating Scales | 5 | 2012 | 782 | 0.160 |
Why?
|
| Trazodone | 1 | 1998 | 5 | 0.160 |
Why?
|
| Priapism | 1 | 1998 | 4 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2009 | 1745 | 0.160 |
Why?
|
| Opioid-Related Disorders | 2 | 2007 | 298 | 0.160 |
Why?
|
| Substance Abuse Treatment Centers | 3 | 2012 | 71 | 0.150 |
Why?
|
| Linear Models | 4 | 2012 | 521 | 0.150 |
Why?
|
| Nicotine | 1 | 2001 | 350 | 0.150 |
Why?
|
| Cardiovascular Agents | 1 | 1998 | 82 | 0.150 |
Why?
|
| Case-Control Studies | 3 | 2014 | 1553 | 0.140 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2015 | 307 | 0.140 |
Why?
|
| Ambulatory Care | 6 | 2012 | 340 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2012 | 468 | 0.140 |
Why?
|
| Arousal | 2 | 2014 | 168 | 0.140 |
Why?
|
| Anti-Anxiety Agents | 3 | 2002 | 107 | 0.140 |
Why?
|
| Patient Compliance | 3 | 2017 | 402 | 0.130 |
Why?
|
| Phobic Disorders | 1 | 1997 | 227 | 0.130 |
Why?
|
| Exercise Therapy | 1 | 2017 | 183 | 0.130 |
Why?
|
| Dopamine | 2 | 2010 | 474 | 0.130 |
Why?
|
| Psychiatric Department, Hospital | 1 | 2015 | 17 | 0.130 |
Why?
|
| Time Factors | 8 | 2014 | 4655 | 0.130 |
Why?
|
| Health Education | 1 | 2017 | 279 | 0.120 |
Why?
|
| Excitatory Amino Acid Transporter 3 | 1 | 2014 | 1 | 0.120 |
Why?
|
| Polymorphism, Genetic | 2 | 2014 | 301 | 0.120 |
Why?
|
| Cognition | 2 | 2011 | 513 | 0.120 |
Why?
|
| Safety Management | 1 | 2015 | 73 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 3259 | 0.120 |
Why?
|
| Mental Disorders | 2 | 2012 | 659 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 2 | 2013 | 329 | 0.110 |
Why?
|
| Varenicline | 1 | 2014 | 98 | 0.110 |
Why?
|
| Acetylcysteine | 2 | 2007 | 296 | 0.110 |
Why?
|
| Antimetabolites | 1 | 2013 | 17 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 627 | 0.110 |
Why?
|
| Aripiprazole | 2 | 2010 | 43 | 0.110 |
Why?
|
| Cycloserine | 1 | 2013 | 30 | 0.110 |
Why?
|
| Patient Safety | 1 | 2015 | 202 | 0.110 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 13 | 0.110 |
Why?
|
| Hospitalization | 3 | 2015 | 978 | 0.110 |
Why?
|
| Comorbidity | 4 | 2015 | 1426 | 0.110 |
Why?
|
| Mental Health Services | 2 | 2012 | 199 | 0.100 |
Why?
|
| Crack Cocaine | 2 | 2006 | 20 | 0.100 |
Why?
|
| Electroencephalography | 2 | 2006 | 418 | 0.100 |
Why?
|
| Video Games | 1 | 2012 | 39 | 0.100 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2012 | 137 | 0.100 |
Why?
|
| Exercise | 1 | 2017 | 658 | 0.100 |
Why?
|
| Gyrus Cinguli | 1 | 2012 | 113 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2013 | 689 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 160 | 0.100 |
Why?
|
| Substance Abuse Detection | 2 | 2002 | 66 | 0.090 |
Why?
|
| Social Environment | 1 | 2012 | 182 | 0.090 |
Why?
|
| Oxygen | 2 | 2013 | 386 | 0.090 |
Why?
|
| Smoking Prevention | 1 | 2012 | 259 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 438 | 0.090 |
Why?
|
| Remote Consultation | 2 | 2012 | 50 | 0.090 |
Why?
|
| Protein Binding | 1 | 2012 | 1027 | 0.090 |
Why?
|
| Aged | 7 | 2013 | 14862 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2005 | 931 | 0.080 |
Why?
|
| Affect | 3 | 2008 | 218 | 0.080 |
Why?
|
| Adolescent | 4 | 2005 | 8912 | 0.070 |
Why?
|
| Prefrontal Cortex | 1 | 2012 | 640 | 0.070 |
Why?
|
| Buprenorphine | 1 | 2007 | 67 | 0.070 |
Why?
|
| Alcohol Withdrawal Seizures | 1 | 2006 | 12 | 0.070 |
Why?
|
| Cerebrovascular Circulation | 1 | 2008 | 296 | 0.070 |
Why?
|
| Surgical Procedures, Operative | 1 | 2007 | 124 | 0.070 |
Why?
|
| Turkey | 1 | 2005 | 7 | 0.070 |
Why?
|
| United States | 6 | 2015 | 7367 | 0.070 |
Why?
|
| Cerebral Cortex | 2 | 2006 | 415 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2008 | 384 | 0.060 |
Why?
|
| Verbal Learning | 1 | 2005 | 29 | 0.060 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2005 | 71 | 0.060 |
Why?
|
| Pain, Postoperative | 1 | 2007 | 214 | 0.060 |
Why?
|
| Memory, Short-Term | 1 | 2005 | 79 | 0.060 |
Why?
|
| Peptide Hormones | 1 | 2004 | 9 | 0.060 |
Why?
|
| Fasting | 1 | 2004 | 75 | 0.060 |
Why?
|
| Ventral Tegmental Area | 1 | 2005 | 74 | 0.060 |
Why?
|
| Neurologic Examination | 2 | 2006 | 107 | 0.060 |
Why?
|
| Health Services | 1 | 2005 | 87 | 0.060 |
Why?
|
| Leptin | 1 | 2004 | 80 | 0.060 |
Why?
|
| Neurotransmitter Agents | 1 | 2004 | 102 | 0.060 |
Why?
|
| Alcoholic Beverages | 1 | 2004 | 18 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 567 | 0.060 |
Why?
|
| Evoked Potentials, Motor | 1 | 2004 | 63 | 0.060 |
Why?
|
| Rest | 1 | 2004 | 78 | 0.060 |
Why?
|
| Beverages | 1 | 2004 | 50 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2012 | 2800 | 0.060 |
Why?
|
| Behavior, Animal | 1 | 2006 | 470 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2005 | 403 | 0.050 |
Why?
|
| Motor Cortex | 1 | 2004 | 158 | 0.050 |
Why?
|
| Bipolar Disorder | 1 | 2005 | 307 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2012 | 7277 | 0.050 |
Why?
|
| Visual Perception | 2 | 2017 | 124 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2007 | 498 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 378 | 0.050 |
Why?
|
| Nucleus Accumbens | 1 | 2005 | 417 | 0.050 |
Why?
|
| Prescription Fees | 1 | 2001 | 5 | 0.050 |
Why?
|
| Ritanserin | 1 | 2001 | 5 | 0.050 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2001 | 8 | 0.050 |
Why?
|
| Serotonin Agents | 1 | 2001 | 13 | 0.050 |
Why?
|
| Vigabatrin | 1 | 2001 | 8 | 0.050 |
Why?
|
| Afghan Campaign 2001- | 2 | 2012 | 78 | 0.050 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2001 | 34 | 0.050 |
Why?
|
| Iraq War, 2003-2011 | 2 | 2012 | 85 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2001 | 88 | 0.050 |
Why?
|
| Sodium Oxybate | 1 | 2001 | 13 | 0.050 |
Why?
|
| Buspirone | 1 | 2001 | 36 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2014 | 737 | 0.050 |
Why?
|
| Sleep Wake Disorders | 1 | 2002 | 94 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 848 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2005 | 445 | 0.040 |
Why?
|
| Personality Inventory | 1 | 2001 | 197 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2001 | 546 | 0.040 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2004 | 413 | 0.040 |
Why?
|
| Placebos | 2 | 2012 | 195 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 2279 | 0.040 |
Why?
|
| Algorithms | 1 | 2004 | 1196 | 0.040 |
Why?
|
| Logistic Models | 2 | 2015 | 1420 | 0.040 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 1998 | 19 | 0.040 |
Why?
|
| Internet | 1 | 2001 | 390 | 0.040 |
Why?
|
| Suicide, Attempted | 1 | 1998 | 72 | 0.040 |
Why?
|
| Drug Interactions | 1 | 1998 | 289 | 0.040 |
Why?
|
| Drug Overdose | 1 | 1998 | 67 | 0.040 |
Why?
|
| Aggression | 1 | 1998 | 98 | 0.040 |
Why?
|
| Temperance | 2 | 2009 | 41 | 0.040 |
Why?
|
| Pharmacogenomic Variants | 1 | 2017 | 15 | 0.040 |
Why?
|
| Clonidine | 1 | 1997 | 66 | 0.040 |
Why?
|
| Sleep | 2 | 2009 | 263 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 249 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2007 | 260 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 4848 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2015 | 120 | 0.030 |
Why?
|
| Suicide | 1 | 2015 | 116 | 0.030 |
Why?
|
| Animals | 3 | 2006 | 20881 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 1997 | 498 | 0.030 |
Why?
|
| Genotype | 1 | 2014 | 786 | 0.030 |
Why?
|
| Prevalence | 1 | 1997 | 1619 | 0.030 |
Why?
|
| Vietnam Conflict | 1 | 2012 | 14 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 2093 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2013 | 213 | 0.020 |
Why?
|
| Rural Health Services | 1 | 2012 | 101 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2012 | 199 | 0.020 |
Why?
|
| Dominance, Cerebral | 1 | 2011 | 65 | 0.020 |
Why?
|
| Risk Factors | 2 | 2014 | 5731 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1266 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1603 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 652 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 955 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2012 | 346 | 0.020 |
Why?
|
| Smoking | 1 | 2017 | 1452 | 0.020 |
Why?
|
| Social Control, Informal | 1 | 2008 | 8 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 334 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2009 | 411 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2011 | 332 | 0.020 |
Why?
|
| Impulsive Behavior | 1 | 2008 | 85 | 0.020 |
Why?
|
| Administration, Sublingual | 1 | 2007 | 15 | 0.020 |
Why?
|
| Naloxone | 1 | 2007 | 56 | 0.020 |
Why?
|
| Inactivation, Metabolic | 1 | 2006 | 28 | 0.020 |
Why?
|
| Diazepam | 1 | 2006 | 23 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2006 | 65 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2006 | 89 | 0.020 |
Why?
|
| Pregabalin | 1 | 2006 | 13 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2006 | 134 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2009 | 335 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2006 | 187 | 0.020 |
Why?
|
| Creatinine | 1 | 2006 | 243 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2006 | 100 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 3705 | 0.020 |
Why?
|
| Self Administration | 1 | 2007 | 419 | 0.020 |
Why?
|
| Patient Selection | 1 | 2009 | 592 | 0.020 |
Why?
|
| Patient Admission | 1 | 2006 | 99 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 201 | 0.020 |
Why?
|
| Korea | 1 | 2004 | 13 | 0.020 |
Why?
|
| Ghrelin | 1 | 2004 | 8 | 0.020 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2005 | 151 | 0.020 |
Why?
|
| Differential Threshold | 1 | 2004 | 27 | 0.020 |
Why?
|
| Hunger | 1 | 2004 | 27 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2004 | 106 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 579 | 0.010 |
Why?
|
| Electromyography | 1 | 2004 | 184 | 0.010 |
Why?
|
| Nonlinear Dynamics | 1 | 2003 | 55 | 0.010 |
Why?
|
| Neural Pathways | 1 | 2005 | 324 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2004 | 291 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 951 | 0.010 |
Why?
|
| Length of Stay | 1 | 2006 | 780 | 0.010 |
Why?
|
| Anger | 1 | 2002 | 47 | 0.010 |
Why?
|
| Work Capacity Evaluation | 1 | 2002 | 8 | 0.010 |
Why?
|
| Self Disclosure | 1 | 2002 | 55 | 0.010 |
Why?
|
| Software | 1 | 2004 | 418 | 0.010 |
Why?
|
| Outpatients | 1 | 2002 | 127 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2004 | 867 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1664 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2005 | 2083 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2000 | 216 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2002 | 792 | 0.010 |
Why?
|
| Anxiety | 1 | 2002 | 422 | 0.010 |
Why?
|
| Self Medication | 1 | 1997 | 25 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 5300 | 0.010 |
Why?
|
| Mice | 1 | 2006 | 8474 | 0.010 |
Why?
|